Digital Asset DirectAgile Therapeutics, Inc.
Contact Details Matt Riley - Head of Investor Relations & Corporate Communications mriley@agiletherapeutics.com Company Website https://agiletherapeutics.com/
October 21, 2022 11:00 AM Eastern Daylight Time
Video
News ReleaseThe Stuttering Foundation
October 22 nd is International Stuttering Awareness Day (ISAD), observed worldwide with a focus on stuttering--a speech disorder characterized by repetition of sounds, syllables, or words; prolongation of sounds; and interruptions in speech known as blocks. This year also marks the 75 th Anniversary of the Stuttering Foundation, founded by the late entrepreneur and philanthropist Malcolm Fraser in 1947, making it the first and largest nonprofit charitable organization in the world working toward the prevention and improved treatment of stuttering. The Foundation is renowned globally for its trusted and timely resources--many available free on its website: StutteringHelp.org. To mark its 75 th anniversary and in observance of International Stuttering Awareness Day, the Stuttering Foundation officially raised its estimate of people who stutter to 80 million people --representing one percent (1%) of the global population. “When my father Malcolm founded the Stuttering Foundation back in 1947, there were an estimated 25 million people who stutter across the globe,” said Jane Fraser, president of the Stuttering Foundation and Malcolm’s daughter. “Today, we raise our estimate to 80 million people who stutter worldwide, more than three times the number from when we began. Over the decades, we’ve expanded our outreach and added many resources for people in more than 137 countries around the world.” The Stuttering Foundation marked the auspicious occasions with the release of: Ask the Stuttering Foundation --This new YouTube channel addresses the dozens of inquiries received by the Foundation daily by telephone, email, and generated on our website. Some of the queries are more common such as parents who are concerned when their preschoolers begin to stutter, or people who stutter of any age reaching out to learn from others who also stutter. Some requests are less common such as pediatricians or speech-language pathologists looking for help for patients with specific needs. Whatever the content, we respond to meet the needs of people who stutter around the globe. For Kids By Kids 2.0 --This lively and engaging 10-minute video features interviews with real students who stutter, speaking opening about their stutter, dealing with teasing, sharing what helps them, and showing how to teach others about stuttering. An animated skateboarder named Kyle narrates the film. The ABCs of Stuttering --This 10-minute video helps parents and teachers understand how stuttering can affect children of all ages in the classroom and is now available for free on the Stuttering Foundation’s YouTube channel. The highlight of the video is the students--Umberto, Kate and Martin--talking openly about their stutter and what helps make them feel more comfortable talking in the classroom. “For more than seven decades, the Stuttering Foundation has served as a trusted resource for the stuttering community, offering brochures, e-books, podcasts, videos, a magazine, virtual learning sessions and multiple social media channels to spread timely and accurate information about stuttering,” added Fraser. About the Stuttering Foundation Malcolm Fraser, a successful businessman who struggled with stuttering, established the nonprofit Stuttering Foundation in 1947 and endowed it throughout his lifetime. The Foundation provides free online resources at StutteringHelp.org for people who stutter and their families, as well as support for research into the causes of stuttering. Visit www.StutteringHelp.org. Contact Details The Stuttering Foundation Greg Wilson +1 571-239-7474 greg@curleycompany.com
October 19, 2022 01:00 PM Eastern Daylight Time
News ReleaseLiveWire Ergogenics, Inc.
The cannabis industry has undergone drastic changes in recent years, and as marijuana becomes more mainstream, consumers are demanding more from cannabis companies. No longer are the days when consumers will settle for a plastic zip lock bag of questionable quality and purity underground weed — they want choices that reflect their lifestyle and values. Many consumers report that they want a high-quality lifestyle brand and one of the things they are looking for is an organic, hand-cut, pesticide-free, and easy-to-consume cannabis product. Companies that embody these values will be better positioned to become the go-to products for more consumers. Why Do Consumers Want Lifestyle Brands? A growing percentage of consumers care more about the quality and sustainability of the brands they engage with. In a recent survey by Stifel and Morning Consult, more than half of the survey’s respondents shared they had bought from a new brand specifically for its transparent, environmentally responsive, and sustainable practice. When it comes to the cannabis industry, there is a preference for hand-trimmed and hand-grown cannabis. Colloquially known as craft cannabis, companies willing to prioritize hand-trimmed cannabis grown without pesticides and machines will have an easier task of creating high-end products that consumers flock to. Cannabis companies would be wise to look to the lifestyle brand journey of other consumer packaged goods (CPG). Researchers see lots of comparisons between the growth of lifestyle brands in high-end coffee companies and the cannabis industry. Similarly to how high-end coffee consumers are more loyal to brands that boost sustainable heritage, product origins, ethical sourcing, and roasts, a growing number of cannabis consumers are following suit. California is in the process of implementing a product origin program similar to the California wine industry for cannabis. Companies that can leverage a consumer-centric approach to the cannabis industry might find success in the coming years as luxury cannabis becomes more available and accessible to the public. What Companies Are Doing It Right? LiveWire Ergogenics Inc. (OTCMKTS: LVVV) (“LiveWire”) is a company that focuses on acquiring and managing special-purpose real estate properties that qualify for the discovery and development of high-end organic cannabis products. Because of this focus on selecting compliant real estate, LiveWire can hone in on projects that allow for high-end cultivation and set the Company apart from the competition, especially from mass producers of low-quality products. In order to operate economically, LiveWire has developed its Estrella Ranch as the central hub for all LiveWire and subsidiary operations. The Estrella Ranch’s location is ideal for cultivating a high-end organic-style product in a micro-climate that can allow for all-year-round production. Its tractor-less operation is focused on producing high-quality, hand-crafted outdoor products. Additionally, the property’s ultimate goal is to be the world’s first Estate Grown Weedery, an ultimate cannabis destination. This goal aligns well with the Company’s health and wellness lifestyle value. Consumers want an experience from their lifestyle brand of choice, and LiveWire seems to be an example of a company positioning itself well to deliver. The Company focuses on acquiring, managing, and licensing well-qualified cannabis real estate locations to establish fully compliant and permitted facilities to produce cannabis-based products and establish relationships for the statewide distribution of these products in California. This includes developing and licensing high-quality organic cannabinoid-based products and services and creating the high-quality "Estrella Grown Weedery™" brand via its subsidiary/affiliate companies Estrella Ranch Partners, Estrella River Farms, Makana Ola, and CaliCruz Farms. LiveWire Ergogenics does not produce, sell, or distribute products that violate the United States Controlled Substances Act. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Tristan Cavato ir@livewireergogenics.com
October 19, 2022 09:24 AM Eastern Daylight Time
News ReleaseLMCC Ventures LLC
New York, NY, October 18, 2022 — Luxury Meets Cannabis Conference (LMCC) today announced the complete program for its Fall 2022 Edition, which returns on October 20 & 21 in Hudson Yards, New York City. Launched in 2018 as a first-of-its-kind B2B trade event, LMCC has grown into the go-to resource and venue for product discovery and extensive category education, connecting visionary CBD and Cannabis brands across the beauty/wellness, food/beverage, and technology/lifestyle accessory categories to mainstream retailer buyers, luxe dispensaries, media, and investors. As an indication of the excitement around the emerging New York legal Cannabis market and the official brand showcase mix at LMCC, 100+ A-tier retail outlets – LMCC’s highest rate to date – have registered to attend the show including KITH, Standard Dose, Curaleaf, Bloomingdale’s, Rise Cannabis, Etain, The Vitamin Shoppe, Shen Beauty, and many others. LMCC’s inaugural infused Food & Beverage Hall will also debut, which will feature the finest food/culinary, beverage, consumables, and confectionery brands in the space — especially timely as alcohol sales in the U.S. continue to decline. This Harrods-esque, immersive (and delectable) experience will spotlight leading brands such Cann, Kiva Confections, oHHo, Cycling Frog, Cloud 11, Black Dahlia, L8, Sass, Chef For Higher, and many more. More than 700 business attendees from around the world will explore the LMCC Official Brand Showcase — a pre-vetted, store-ready exhibition — paired with a full schedule of keynote talks, brand presentations, and business networking. For the most up-to-date information on partners, exhibiting brands and speakers, visit lmccshow.com. LMCC FALL 2022 OFFICIAL BRAND SHOWCASE DIRECTORY Astraèa & Co. Black Dahlia CANDOR CANN Chef for Higher Cloud 11 Cycling Frog Daily Habit Drew Martin errbshop Franny’s Farmacy Function Botanicals The Healing Rose Hudson Cannabis Innocan Pharma K’dara Kiva L8 LEUNE LumiBloom MĀSK Skincare oHHo Plantwise REUNION Sackville & Co. SASS StellaVia Stone Road UB Super / Meticulous Skincare WALALA LMCC SPEAKER SCHEDULE NOW LIVE See 50 leading executives on stage from Ulta Beauty, Adweek, New York State Cannabis Control Board, Merida Capital Holdings, Adweek, Different Leaf, NYC Mayor’s Office, Food & Wine, Standard Dose, Women’s Health, and Bon Appétit and many others: View LMCC Fall 2022 Speaker Schedule Here ### Attendee Tickets: Two-day, all-access passes to LMCC 2022 are $695. Purchase passes HERE. Retail Buyer Registration: Admission is complimentary only for qualified retail buyers and their teams. Stores, dispensaries, and e-tailers only can register HERE. Sponsors: LMCC is proud to partner with Merida Capital Holdings Brand Applications: Now Accepting Submission for LMCC May 2023 Brands Can Now Reserve Space for LMCC 2023 Here About LMCC: Founded in 2018, LMCC Ventures LLC is the parent company of the annual Luxury Meets Cannabis* Conference (LMCC) in New York City. LMCC is the premier B2B event connecting A-tier retailers, media, investors, leading dispensaries and CPG executives to premium CBD, hemp and Cannabis brands — with a keen focus on beauty, wellness, food & beverage. Past participants include retailers like Sephora, Nordstrom, Credo Beauty, and Bloomingdale’s; media including The New York Times, Glossy, Travel & Leisure, O, The Oprah Magazine, and Robb Report; and speakers from Mitch Baruchowitz (Merida Capital Holdings) and Cindy Capobianco (Lord Jones) to Bobbi Brown and Frederic Fekkai. For more information on LMCC, visit lmccshow.com. Find LMCC socially on LinkedIn and Instagram. Guidelines & Legal: no smoking or vaping on any kind permitted inside the venue. Local laws strictly apply. Contact Details Katie Shapiro +1 303-882-5596 katie@katieshapiromedia.com Company Website https://www.lmccshow.com/
October 19, 2022 09:00 AM Eastern Daylight Time
Digital Asset DirectChill Brands Group PLC
Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
October 19, 2022 06:51 AM Eastern Daylight Time
Video
News ReleaseYourUpdateTV
October 15 marked the start of the Medicare Annual Enrollment Period — a time for Medicare-eligible people to choose the plan that best supports their unique needs and budget. Recently, Vice President of Aetna Medicare Bob O’Connor, participated in a nationwide satellite media tour to discuss what you need to know for thisAnnual Enrollment Period. A video accompanying this announcement is available at: https://youtu.be/jriqOx0-9pc With the national inflation rate at an all-time high since the 1980s, it’s more important than ever for older adults, who are often on a fixed income, to evaluate their individual health care needs and choose a Medicare plan that best supports those needs in a cost-effective way. The 2022 Health Care Insights Study by CVS Health found that 90 percent of providers said cost of care is a top concern for their 65-and-older patients. Medicare can be confusing because there are a lot of different options out there. And if you’re around Medicare age, your mailbox will soon be flooded with Medicare plan letters, postcards and ads. Think about what’s important to you and ask yourself some basic questions, like does the plan fit your budget and does your plan cover your doctors, hospitals, and pharmacies? Another important thing to consider is prescription drugs. Are there prescription drugs you take regularly? Does the plan’s drug list cover those prescriptions? It’s also important to know what tier your prescription drugs are on or whether there are any coverage rules. The first thing people should do is go to the Medicare.gov website. Once there, they can enter their zip code and see all the Medicare plans available in their area. And of course, you can learn more about 2023 Aetna Medicare plans at AetnaMedicare.com or call us at 1-844-588-0041 (TTY: 711), 7 days a week, 8 AM to 8 PM. The Medicare Annual Enrollment Period runs from October 15 through December 7, 2022. A licensed agent may answer your call. About Bob O’Connor As Vice President of Aetna Medicare and community volunteer for organizations focused on seniors and the disabled, Bob O’Connor brings a unique perspective to the Medicare conversation. He’s worked in several roles at Aetna in support of seniors and currently oversees member experience, quality and business strategy for Aetna’s robust portfolio of Medicare Advantage plans. An advocate for the aging population, Bob is passionate about improving health care and helping Aetna’s more than 10.6 million Medicare members nationwide achieve their best health. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com
October 18, 2022 12:37 PM Eastern Daylight Time
Video
News ReleaseJupiter Wellness, Inc.
Learn More about Jupiter Wellness Inc. by gaining access to the latest research report Breast cancer has surpassed lung cancer as the most commonly diagnosed cancer globally as of 2021, according to the American Cancer Society and the International Agency for Research on Cancer. Although breast cancer is one of the more talked-about cancers, there are many disturbing facts related to this deadly disease that make it more alarming than other cancers. Stats Show Breast Cancer Continues To Wreak Havoc On Women’s Lives Here are some of the latest stats: About 1 in 8 U.S. women (about 13%) will develop invasive breast cancer over the course of their lifetimes. As of January 2022, there are more than 3.8 million women with a history of breast cancer in the U.S., including women currently being treated and women who have finished treatment. In 2022, an estimated 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S. Breast cancer affects men, too, and about 2,710 new cases of invasive breast cancer are expected to be diagnosed in men in 2022 with a man’s lifetime risk of breast cancer being about 1 in 833. About 43,250 women in the U.S. are expected to die of breast cancer in 2022. Death rates have been steady in women under 50 since 2007 but have continued to drop in women over 50 because of screening and early detection and care. About 85% of breast cancers occur in women who have no family history of breast cancer. These occur because of genetic mutations that happen as a result of the aging process and lifestyle — less than 15% of women who get breast cancer have a family member diagnosed with it. Several pharmaceutical companies including Bristol-Myers Squibb Co. (NYSE: BMY), Merck & Co. Inc. (NYSE: MRK), Medivation Inc. (NASDAQ: MDVN), and Pfizer Inc. (NYSE: PFE) have reported developing breakthrough drugs to treat breast cancer over the years. And considerable progress has been made in reducing cancer rates and improving cancer survival through improved diagnostic and treatment modalities, according to reports. Yet the adverse effects of cancer treatment continue to cause concern and unhappiness for breast cancer survivors. Following breast cancer treatment or surgery, some women experience a number of side effects, including a change in body weight, tightness of the skin, changes in sensation, phantom breast sensations (in surgery patients), and loss of sexual desire (libido). The sexual health of women and female libido have always been awkward topics of conversation that are seldom discussed openly. Women don’t want to talk about it and it seems little attention has been paid to developing drugs catering to female sexual wellness. And, by extension, their male partners. A Side Effect That Could Regenerate Libido? Spark Joy? But one Florida-based BioPharma company has licensed a breakthrough product with a novel mechanism of action for women’s sexual wellness. As per a recent press release, “The exclusive license includes issued patents and technology, including formulations. In clinical studies, one topical formulation improved nipple sensitivity and alleviated associated sexual problems. Concomitantly, the formulation was also shown to increase female sexual lubrication and improve overall orgasmic response.” Jupiter Wellness Inc. (NASDAQ: JUPW) reports that its proposed drug, JW-500, when topically applied to the nipple-areola area of the breast, contracts the smooth muscle, thus erecting the nipple and increasing its sensitivity. The company reports that clinical trials of JW-500 have shown efficacy and safety in improving female nipple sensitivity. Further testing is being conducted to quantify and qualify enhanced sexual arousal, vaginal lubrication, and orgasm response in healthy women and women suffering from nipple naturopathy following breast cancer treatment. "This treatment has the potential to address a wide range of clinical indications, including nipple neuropathies following breast augmentation in breast cancer survivors”, said Jupiter Wellness CEO Brian John."We are excited to complete the research and development of this product and to bring this novel approach to the market. I believe this product may not only be an excellent treatment for people with breast cancer but potentially as a women's sexual health product as well." The company plans to file for a pre-IND meeting with the US FDA within the next 12 months and intends to seek Orphan Drug Designation for JW-500. Considering the size of the market for breast cancer survivors and the possibility of addressing libido loss in post-menopausal women, Jupiter Wellness may be a company to keep an eye out for news on their clinical progress. To learn more about JW-500 and Jupiter Wellness, visit its webpage. We support health and wellness through the research and development of over-the-counter (OTC) products and intellectual property. Our product pipeline addresses a range of conditions, including hair loss, eczema, burns, and sexual wellness. Revenue is generated through the sales of OTC and consumer products, contract research agreements, and licensing royalties. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details TraDigital IR- Camille Baptiste camille@tradigitalir.com Company Website https://jupiterwellness.com/
October 18, 2022 09:09 AM Eastern Daylight Time
News ReleaseReady for Ron
Ready for Ron, the only credible independent group working to Draft Florida Governor Ron DeSantis to run for President, announced a new initiative to engage college students, as activists and volunteers, in support of the official national petition to draft Ron DeSantis to run in 2024. ‘Young Americans Ready for Ron’ led by Dylan Dean, will build a nationwide network of student activists to actively engage their fellow students and their local communities as part of the growing national movement in support of a Presidential run by Governor DeSantis. Dean, a student at Montana State University served as a multi-State Chair for the renowned student activist movement Young Americans for Liberty (running five states at once) and is a tireless advocate on and off college campuses. Dean’s experience in grassroots organizing and action has helped him build a national network of Young Americans ready to engage in electoral activism. “My generation is Ready for Ron to continue defending freedom and liberty - just as he has done in Florida – but on the national stage. Since the onset of the COVID-19 pandemic, Governor DeSantis refused to kowtow to the radical Left, keeping the Sunshine State open for business and rejecting the impulse to impose onerous mask and vaccine mandates on citizens of the state. It revealed true bravery and respect for liberty, and that's why I support him now," Dylan Dean said. “By choosing guidelines over mandates, Governor DeSantis has given hope to college students like myself, who can now look to 2024 with newfound optimism that he will win the White House,” Dean continued. For those still in the college system or who just left it, we know what a broken system looks like and how important it is to solve the problems. Only strong leadership can get that job done.” “We are thrilled to have Dylan involved with this effort,” stated Ready for Ron Chief Political Strategist Ed Rollins. We need more younger people involved to grow a powerful apparatus nationwide to draft and elect Ron DeSantis for President. Their future and ours depend on it.” Since its launch in late May, Ready for Ron has enlisted nearly one hundred thousand supporters, generated significant media attention, and run hundreds of ads to convince Ron DeSantis to run for President. Ready for Ron has emerged as the only credible independent organization in support of a Ron DeSantis candidacy. Americans are encouraged to sign the petition at ReadyForRon.com to draft Ron DeSantis to run in 2024. ### Contact Details Dan Rene +1 202-329-8357 dan@readyforron.com Company Website https://www.readyforron.com/
October 18, 2022 08:45 AM Eastern Daylight Time
News ReleaseAllarity Therapeutics, Inc.
Once brought into its pipeline, Allarity uses its DRP® platform to develop companion diagnostics alongside each drug to improve the treatments in a personalized medicine approach. Earlier this year, the company refocused its pipeline strategy toward combination therapies in an effort to improve treatment outcomes while also creating more funding and partnership opportunities. Allarity Therapeutics Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on oncology treatments. After decades of research, the company has created what it describes as a powerful next-generation companion diagnostics platform, called Drug Response Predictor (DRP®), and is now developing a portfolio of promising cancer treatments. Companion Diagnostics Are Helping Doctors Deliver The Right Cancer Treatment To The Right Patient At The Right Time Companion diagnostic tests help doctors quickly and accurately identify which treatments a particular person is most likely to respond to so that they can develop a personalized treatment plan that has the highest odds of being successful for that cancer patient. Earlier versions of these tests would look at a single gene or a small handful of genes known to be predictors of treatment response. This can provide a limited view of the patient’s potential response. Take, for example, the epidermal growth factor receptor (EGFR) expressed in some colorectal cancers. A test identifying this biomarker might identify the patient as a candidate for anti-EGFR therapy. However, tumors with EGFR alongside KRAS or NRAS mutations are often resistant to anti-EGFR therapy. But if the test isn’t looking at that biomarker of resistance, it could misidentify them as a candidate for the therapy when they really aren’t. To account for those limitations, the next generation of diagnostic tests is broadening the scope. Foundation Medicine Inc.’s FoundationFocus CDx, for example, was the first companion diagnostic assay approved by the Food and Drug Administration (FDA). It analyzes 324 genes to predict responsiveness to treatments for five types of cancer. Similarly, Myriad Genetics Inc. (NASDAQ: MYGN) launched its new Precise Tumor test earlier this year that analyzes over 500 tumor-related genes. However, these are still constrained by the limits of the biomarkers science has identified so far. That means biomarkers of resistance or responsiveness that researchers don’t know about yet could impact the accuracy of the results. Allarity’s Proprietary Drug Response Predictor Platform Reported To Deliver Even More Precision Allarity’s Drug Response Predictor (DRP®) platform is a unique bioanalytical platform that can create drug-specific predictive diagnostics for a wide range of cancer treatments. Unlike other companion diagnostics on the market, Allarity’s DRP® looks at the entire 25,000-plus genes expressed in a cancer cell — not just the ones science has already identified as biomarkers of responsiveness. Over the past two decades, the company has developed this platform through dozens of clinical trials and the analysis of thousands of human tumor biopsy samples to create the robust platform. The result is a platform that can bridge the gap between how cancer cells respond to a given drug in vitro versus how actual patient tumors respond. It can then create drug-specific biomarker signatures, a set of 50 to 400 genes that predict how a patient’s cancer is likely to respond to a specific treatment. A DRP® companion diagnostic delivers its results in the form of a score on a color-coded spectrum where green means the patient is a high match, likely to respond to a drug, and red means the patient is unlikely to respond because they have too many genes predicting resistance to that treatment. In other words, the DRP® not only identifies likely candidates for a drug but also rules out unlikely responders so doctors can more effectively narrow in on the best treatment options for each patient. This precision has yielded promising results in clinical trials. Across the dozens of clinical trials done to develop this platform, DRP® has shown it offers twofold to fivefold improvements in overall response rate or time to progression compared to patients not selected with the DRP® companion diagnostic. The DRP® platform has been extensively published in peer-reviewed scientific journals and is patented. This genome-wide scope covering all 25,000-plus cancer genes gives Allarity the ability to develop a companion diagnostic for every drug it brings into its pipeline as well as partner with other companies to develop tests for the drugs in their pipelines. A Low-Risk Pipeline Of Promising Oncology Drug Candidates? The Massachusetts-based pharmaceutical has minimized the risks associated with drug development by only having acquired drug candidates from other companies, including big pharma, that have already demonstrated safety and efficacy in early trials. Most of Allarity’s pipeline programs are former big pharma assets that have progressed past Phase 1 studies or later Phase 2/3 studies. Stenoparib, for example, is being evaluated as a treatment for ovarian cancer. Allarity licensed it from Eisai Co. Ltd. (OTCMKTS: ESALY). It now planning to evaluate stenoparib in combination with dovitinib, a drug candidate with multiple indications that Allarity licensed from Novartis AG (NYSE: NVS). Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP® platform. The Company has a mature portfolio of five drug candidates: stenoparib, a PARP inhibitor in Phase 2 development for ovarian cancer; dovitinib, a post-Phase 3 pan-tyrosine kinase inhibitor; IXEMPRA® (Ixabepilone), a microtubule inhibitor approved in the U.S. for the treatment of second-line metastatic breast cancer and in Phase 2 development in Europe for the same indication; and 2X-111, a liposomal formulation of doxorubicin in Phase 2 development for metastatic breast cancer and/or glioblastoma multiforme (GBM), which is the subject of discussions for a restructured out-license to Smerud Medical Research International AS. LiPlaCis®, a liposomal formulation of cisplatin and its accompanying DRP® is being developed via a partnership with Chosa ApS, an affiliate of Smerud Medical Research International, for late-stage metastatic breast cancer. The Company is headquartered in the United States and maintains an R&D facility in Hoersholm, Denmark. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Thomas Pedersen tsp@carrotize.com Company Website https://allarity.com/
October 18, 2022 08:00 AM Eastern Daylight Time
Contact Us
Pricing
About us
Features
News Hub
Terms of Use
Privacy Policy